

REMARKS

Responsive to the Restriction Requirement mailed September 26, 2003, Applicant hereby elects Group IV drawn to a method of modulating hexose uptake and methods of treatment via GLUTX nucleic acid expression modulation and methods of identifying inhibitors of GLUTX gene expression (Claims 20, 21, 24-28, 32). Applicant reserves the right to prosecute non-elected subject matter in this or subsequent applications. Claims to non-elected subject matter have been cancelled herein.

This paper is being filed timely and it is believed no additional extensions of time or fees are required. In the event any extensions of time or fees are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.


Entry of the remarks made herein is respectfully requested.

27 October 2003 (Monday)

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

By



Kerri Pollard Schray
Registration No. 47,066
75 Sidney Street
Cambridge, MA 02139
Telephone - 617-551-3676
Facsimile - 617-551-8820